A two-count declaratory judgment action for non-infringement of U.S. Patent Nos. 6,916,941 and 7,420,069, which are listed in the U.S. Food and Drug Administration’s Orange Book for Lexapro, filed by…
Infosint S.A.’s Irish patent has been revoked following a UK trial court ruling in a patent infringement suit it filed against Forest and H. Lundbeck A/S, a unit of Forest…
Forest Laboratories Inc. disclosed that on April 14, 2011, the trial court rendered judgment that Infosint S.A.’s UK patent is invalid.
During the quarter ended December 31, 2009, Infosint commenced comparable…
Forest Laboratories Inc. disclosed that on March 11, 2011, the Federal Circuit affirmed a ruling invalidating Infosint S.A.’s patent.
In April 2006, an action was commenced in the United States District…
A declaratory judgment action filed by Apotex Inc. against Forest Laboratories Inc. is pending.
On Jan. 10, 2011, Apotex Inc. filed a two-count declaratory judgment action against Forest and H. Lundbeck…
Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH have entered into settlement agreements with all remaining defendants in patent infringement litigation…
A new trial date has yet to be set for Forest Laboratories Inc.’s patent infringement complaint against Mylan.
In January 2008, Forest Laboratories and Merz, the Company’s licensor for Namenda, commenced…
Forest Laboratories Inc. and other defendants’ motions to dismiss
RxUSA Wholesale, Inc.’s patent infringement suit are pending on
appeal before the United States Court of Appeals for the Second
Circuit.
On July 14, 2006,…
Forest Laboratories Inc. plans to appeal a jury verdict on Infosint S.A.’s patent infringement suit to the U.S. Court of Appeals for the Federal Circuit.
In April 2006, an action was…
The settlement of the patent infringement suit captioned “Forest Laboratories, Inc. et al. v. Caraco Pharmaceutical Laboratories, Ltd. et al.,” remains subject to review by the U.S. Federal Trade Commission.
In…